C4Insights® - Special: Shaping the future together 

Evonik Oxeno, a wholly-owned subsidiary of Evonik, is a leading company in C4 chemistry with 50 years of experience, operating two world-scale C4 production facilities in Marl and Antwerp. The flexibility of its integrated network allows Oxeno to quickly and efficiently respond to changing conditions in supply and demand, optimizing the complexity of value chains also for its suppliers and customers. Oxeno is recognized for its focus on innovation and sustainability, maintaining an impressive portfolio of approximately 2,100 patents and patent applications. Its C4 strategy is based on a solid foundation and defined measures for growth and transformation. The company’s vision, “Chemistry4Future® – We increase the value of C4 chemicals sustainably,” outlines its long-term goal and provides a clear idea of where it aims to see its business in the future.

Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €14.1 billion and earnings (adjusted EBITDA) of €1.9 billion in 2025. The common motivation of the approximately 31,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day.

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.